2026-05-16T23:16:55Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/88002024-03-12T11:11:47Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220

Santos García, Diego Deus-Fonticoba, Teresa de González, José Manuel Paz Bartolomé, Carlos Cores Valdés Aymerich, Lorena Enríquez Muñoz, J. G. Suárez, Esther Jesús, Silvia Aguilar, Miquel Pastor, Pau Planellás, Lluis L. Cosgaya, Marina García Caldentey, Juan Caballol, Núria Legarda, Inés Hernández Vara, Jorge Cabo López, Iria López Manzanares, Lydia González Aramburu, Isabel Ávila Rivera, María A. Catalán, María José Nogueira, Víctor Puente, Víctor García Moreno, José Manuel Borrue, Carmen Solano Vila, Berta Álvarez Saúco, María Vela Desojo, Lydia Escalante Arroyo, Sonia Cubo Delgado, Esther Carrillo Padilla, Francisco Martínez Castrillo, Juan Carlos Sánchez Alonso, Pilar Alonso Losada, María Gema López Ariztegui, Nuria Gastón, Itziar Kulisevsky Bojarsky, Jaume Blázquez Estrada, Marta Seijo, Manuel Ruíz Martínez, Javier Valero, Caridad Kurtis, Mónica M. Fabregues, Oriol de González Ardura, Jessica Ordás Bandera, Carlos Manuel López Díaz, Luis M. Mir, Pablo Martínez Martín, Pablo COPPADIS Study Group Introduction. In a degenerative disorder such as Parkinson’s disease (PD), it is important to establish clinical stages that allow to know the course of the disease. Our aim was to analyze whether a scale combining Hoehn and Yahr’s motor stage (H&Y) and the nonmotor symptoms burden (NMSB) (assessed by the nonmotor symptoms scale (NMSS)) provides information about the disability and the patient’s quality of life (QoL) with regard to a defined clinical stage. Materials and Methods. Cross-sectional study in which 603 PD patients from the COPPADIS cohort were classified according to H&Y (1, stage I; 2, stage II; 3, stage III; 4, stage IV/V) and NMSB (A: NMSS = 0–20; B: NMSS = 21–40; C: NMSS = 41–70; D: NMSS ≥ 71) in 16 stages (HY.NMSB, from 1A to 4D). QoL was assessed with the PDQ-39SI, PQ-10, and EUROHIS-QOL8 and disability with the Schwab&England ADL (Activities of Daily Living) scale. Results. A worse QoL and greater disability were observed at a higher stage of H&Y and NMSB (). Combining both (HY.NMSB), patients in stages 1C and 1D and 2C and 2D had significantly worse QoL and/or less autonomy for ADL than those in stages 2A and 2B and 3A and 3B, respectively (; e.g., PDQ-39SI in 1D [n = 15] vs 2A [n = 101]: 28.6 ± 17.1 vs 7.9 ± 5.8; ). Conclusion. The HY.NMSB scale is simple and reflects the degree of patient involvement more accurately than the H&Y. Patients with a lower H&Y stage may be more affected if they have a greater NMS burden. 2024-03-11 2024-03-11 2021-05 info:eu-repo/semantics/article 2090-8083 http://hdl.handle.net/10259/8800 10.1155/2021/8871549 2042-0080 eng Parkinson's Disease. 2021, V. 2021, p. 1-16 https://doi.org/10.1155/2021/8871549 http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Atribución 4.0 Internacional Hindawi